MaxCyte, Inc. (MXCT) stock
MXCTNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 9/3065% below fair value
$1.17−0.01 (-0.85%)
Close on Nov 17, 2026Market cap $120.75MP/E –Yield –
MaxCyte net income
Net income is the profit left for shareholders after every expense, interest and tax.
MaxCyte's net income for the twelve months ending Jun 30, 2026 was -$35.64M. For fiscal 2025 it was -$44.63M. The highest annual figure on record is -$11.82M in fiscal 2020.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$44.63M | – |
| FY2024 | Dec 31, 2024 | -$41.06M | – |
| FY2023 | Dec 31, 2023 | -$37.92M | – |
| FY2022 | Dec 31, 2022 | -$23.57M | – |
| FY2021 | Dec 31, 2021 | -$19.08M | – |
| FY2020 | Dec 31, 2020 | -$11.82M | – |
| FY2019 | Dec 31, 2019 | -$12.90M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$8.87M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.75M | – |
| Q4 FY2025 | Dec 31, 2025 | -$9.60M | – |
| Q3 FY2025 | Sep 30, 2025 | -$12.42M | – |
| Q2 FY2025 | Jun 30, 2025 | -$12.36M | – |
| Q1 FY2025 | Mar 31, 2025 | -$10.26M | – |
| Q4 FY2024 | Dec 31, 2024 | -$10.60M | – |
| Q3 FY2024 | Sep 30, 2024 | -$11.56M | – |
| Q2 FY2024 | Jun 30, 2024 | -$9.38M | – |
| Q1 FY2024 | Mar 31, 2024 | -$9.53M | – |
| Q4 FY2023 | Dec 31, 2023 | -$5.28M | – |
| Q3 FY2023 | Sep 30, 2023 | -$11.25M | – |
| Q2 FY2023 | Jun 30, 2023 | -$10.51M | – |
| Q1 FY2023 | Mar 31, 2023 | -$10.88M | – |
| Q4 FY2022 | Dec 31, 2022 | -$4.81M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.43M | – |
| Q2 FY2022 | Jun 30, 2022 | -$8.26M | – |
| Q1 FY2022 | Mar 31, 2022 | -$4.07M | – |
| Q4 FY2021 | Dec 31, 2021 | -$4.87M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.68M | – |
| Q2 FY2021 | Jun 30, 2021 | -$4.42M | – |
| Q1 FY2021 | Mar 31, 2021 | -$7.11M | – |
| Q4 FY2020 | Dec 31, 2020 | -$2.65M | – |
| Q3 FY2020 | Sep 30, 2020 | -$3.10M | – |
| Q2 FY2020 | Jun 30, 2020 | -$3.00M | – |
| Q1 FY2020 | Mar 31, 2020 | -$3.06M | – |
See a number that looks wrong?